fashion -WSS

fashion

author：entertainment 2025-09-27 13:04:18 - browse：57

a person wearing blue dress conducts a finger prick test on another person in a home setting — coverage from STAT — Adobe

The last decade has seen billions of dollars flow into digital health companies that promise to improve outcomes for the 38 million Americans living with type 2 diabetes. Their products aren’t cheap, but in the long term, they pitch to health plans and employers that these digital tools will help cut health care costs by preventing serious complications like amputation and kidney failure.

A systematic review by the Peterson Health Technology Institute found, though, that digital tools used to manage diabetes with the help of finger-stick blood glucose readings don’t result in clinically meaningful improvements over standard care. As a result, they don’t reduce health care spending — they drive it up.

“Most of the solutions in this category do not deliver clinical benefits that justify their cost,” Caroline Pearson, executive director of the institute, told STAT. Despite finding that some populations may benefit, the report concludes that current evidence doesn’t support broader adoption for most products.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： STAT Summit: Michael J. Fox on progress in Parkinson's research

knowledge

WSS

Study suggests Covid rebound is far more common with Paxlovid than without

STAT Readout Newsletter: Today's biggest biotech updates

How state and local governments are sidelining science

Weight loss drugs should be covered by insurers, AMA says

CEOs share strategies for surviving biotech slump

Eli Lilly expects to double planned employment in Boston center

focus

fashion

focus

The cancer drug shortage isn’t new — and neither are the solutions

The EU Joint Clinical Assessment needs to live up to its promise

ChatGPT in medicine: STAT answers readers' burning questions

STAT Readout Newsletter: Today's biggest biotech updates

BioMarin wins approval for gene therapy to treat hemophilia A

Studies point to risks of excluding people with obesity from drug trials

Wildfire smoke exposes gaps in outdoor worker protections

2023 STAT Wunderkinds: get to know the winners

How to save PrEP access — and even expand it

Medicare’s new pay boost for primary care is angering specialists

entertainment

Senate committee scrutinizes Medicare Advantage brokers

FDA reorg will put new emphasis on investigations, sources say

A letter from the executive editor: STAT UnitedHealth investigation

STAT Summit: Biotech founders on deal

CEOs share strategies for surviving biotech slump

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

hotspot

knowledge

focus

hotspot